| Literature DB >> 30404716 |
Abstract
Recent reports imply, that denosumab discontinuation may lead to an increased risk of multiple vertebral fractures. This is a case report about two postmenopausal women, both with previous fragility fractures, who presented multiple vertebral fractures after denosumab discontinuation. One of the women also had symptomatic hypoparathyroid hypercalcaemia, six months after denosumab was discontinued. We recommend, that denosumab treatment should not be stopped without considering an alternative treatment.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30404716
Source DB: PubMed Journal: Ugeskr Laeger ISSN: 0041-5782